3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
3
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Sleep Initiation and Maintenance Disorders
1
Rectal Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Leucovorin
4
Fluorouracil
3
Oxaliplatin
2
Laparoscopy
2
Cetuximab
2
Capecitabine
2
tislelizumab
1
ferric maltol
1
envafolimab
1
Tranexamic Acid
1
Surgical Procedures, Operative
1
Ropivacaine
1
Propofol
1
Preoperative Exercise
1
Positron Emission Tomography Computed Tomography
1
Nivolumab
1
Nitrous Oxide
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Motivational Interviewing
1
Isoflurane
1
Irinotecan
1
Ipilimumab
1
Immunohistochemistry
1
HMPL-013
1
Folfox protocol
1
Filgrastim
1
Fentanyl
1
Epinephrine
1
Endoscopic Mucosal Resection
1
Drug Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Colonic Neoplasms
×
Filgrastim
×
Clear all
NCT00557102
2012-12-11
ERBIFORT
National Cancer Institute, France
Phase 2
Completed
24 enrolled